HAP Trading’s Enanta Pharmaceuticals ENTA Stock Holding History

HAP Trading’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-27,900	Closed	-$282K	–	1661
2020 Q2	$282K	Buy	+27,900	New	+$1.44M	0.02%	597

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HAP Trading's ENTA Position: Q3 2020 in Review

HAP Trading sold out of Enanta Pharmaceuticals (ENTA) in Q3 2020, closing a stake of 21,189 shares — an estimated $1.06M sold.

HAP Trading first reported a position in ENTA in Q2 2020 and held it in 1 quarter. The position peaked at $1.06M in Q2 2020. 172 funds tracked by Wall St. Rank hold ENTA as of Q3 2020.

HAP Trading reported no remaining Enanta Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
HAP Trading sold 21,189 Enanta Pharmaceuticals shares in Q3 2020, an estimated $1.06M.
HAP Trading first reported a position in Enanta Pharmaceuticals in Q2 2020 and held it in 1 quarter.
HAP Trading's Enanta Pharmaceuticals position peaked at $1.06M in Q2 2020.
172 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2020.

Based on HAP Trading's 13F filing for Q3 2020, filed 13 Nov 2020.